RMD vs BAX — Key Metrics
| Metric | RMD (RESMED INC) | BAX (BAXTER INTERNATIONAL INC) |
|---|---|---|
| Price | 221.1 | 24.0 |
| Market Cap | 31.89 Billion | 12.41 Billion |
| P/E (TTM) | 21.12 | -11.54 |
| P/B (Quarterly) | 4.967 | 2.228 |
| P/S (TTM) | 5.64 | 1.08 |
| Net Profit Margin (TTM) | 26.9 | -9.3 |
| Gross Margin (TTM) | 61.1 | 30.1 |
| ROE (TTM) | 23.9 | -16.6 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
RMD · RESMED INC
Underperform
BAX · BAXTER INTERNATIONAL INC
Greatly Outperform
Recommendation Summary
Stock RMD is projected to underperform the market, stock BAX is projected to greatly outperform the market. Upfront Recommendation: BAX.
Financial Metrics
Prices delayed ~15 min
| RMD | Metrics | BAX |
|---|---|---|
| $221.10 | Price | $24.00 |
| — | Market Capitalization | — |
| 5.64 | Price to Sales | 1.08 |
| 19.34 | Price to FCF Ratio | 15.28 |
| 9.24 | Price to Gross Profit | 3.6 |
| 84.31 | Price to R&D | 24.23 |
| 7.37 | Price to Current Assets | 1.78 |